# Porfiromycin Used as an Adjuvant to Radiation Therapy in Postoperative Head and Neck Cancer Patients

> **NCT02183246** · PHASE3 · TERMINATED · sponsor: **Boehringer Ingelheim** · enrollment: 3 (actual)

## Conditions studied

- Head and Neck Neoplasms

## Interventions

- **DRUG:** Porfiromycin
- **DRUG:** Placebo
- **RADIATION:** Radiotherapy

## Key facts

- **NCT ID:** NCT02183246
- **Lead sponsor:** Boehringer Ingelheim
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2000-05
- **Primary completion:** 2000-12
- **Final completion:** —
- **Target enrollment:** 3 (ACTUAL)
- **Last updated:** 2014-07-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02183246

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02183246, "Porfiromycin Used as an Adjuvant to Radiation Therapy in Postoperative Head and Neck Cancer Patients". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT02183246. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*